Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia

Hematology

Volumn 14, Issue 3, 2009, Pages 133-138

  Oka, Satoko ^a   Muroi, Kazuo ^a   Matsuyama, Tomohiro ^a   Sato, Kazuya ^a   Ueda, Masuzu ^a   Toshima, Masaki ^a   Suzuki, Takahiro ^a   Ozaki, Katsutoshi ^a   Mori, Masaki ^a   Takubo, Takayuki ^b   Nagai, Tadashi ^a   Hanafusa, Toshiaki ^b   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Acute myeloblastic leukemia; Bone marrow; Flow cytometry; Myeloblast

Indexed keywords

CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; CD45 ANTIGEN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CELL SELECTION; CELL STRUCTURE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELOBLAST; PHENOTYPE; PRIORITY JOURNAL; ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW; BONE MARROW CELL; CYTOLOGY; GRANULOCYTE PRECURSOR; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW; BONE MARROW CELLS; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHENOTYPE;

EID: 67949123323     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X402269     Document Type: Article

References (19)

1. Bain B, Catovsky D. Current concerns in haematology. 2: Classification of acute leukaemia. J Clin Pathol 1990; 43: 882-887.
2. Cheson BD, Bennett JM, Kopecky KJ et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
3. McKenna RW, Washington LT, Aquino DB et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-2507.
4. Muroi K, Amemiya Y, Sievers EL et al: Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Leuk Lymphoma 1997; 25: 403-414.
5. Sievers EL, Loken MR. Detection of minimal residual disease in acute myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 123-133.
6. Miyawaki S, Sakamaki H, Ohtake S et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML97 study. Cancer 2005; 104: 2726-2734.
7. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
8. Maslak P. http://ashimagebank.hematologylibrary.org (2003 and 2004).
9. Novotny JR, Schmücker U, Staats B et al. Failed or inadequate bone marrow aspiration: a fast, simple and cost-effective method to produce a cell suspension from a core biopsy specimen. Clin Lab Haematol 2005; 27: 33-40.
10. Kantarjian H, Dixon D, Keating M et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1998; 61: 1441-1446.
11. Germing U, Strupp C, Kuendgen A et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006; 91: 1596-1604.
12. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2006: 199-204.
13. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15-29.
14. Marisavljević D, Rolović Z, Cemerikić V et al. Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol 2004; 21: 325-331.
15. Rainer RO, Hodges L, Seltzer GT. CD 45 gating correlates with bone marrow differential. Cytometry 1995; 22: 139-145.
16. Terstappen LW, Levin J. Bone marrow cell differential counts obtained by multidimensional flow cytometry. Blood Cells 1992; 18: 311-330.
17. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993; 677: 265-280.
18. Loken MR, van de Loosdrecht A, Ogata K et al. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008; 32: 5-17. (Pubitemid 350100844)
19. Jelic TM, Mellen PF, Zavieh K et al. Correlation between the percentages of myeloblasts in bone marrow obtained by flow cytometry and manual counting on glass slide smears in 74 hematologic patients. Leuk Lymphoma 2002; 43: 1927-1931